Trials show small benefit, but without statistical validity Roche setback leaves Biogen and Eisai as leaders in the field It’s up to Roche’s CEO-designate to revive development fortunes Roche shares down 3.4%, its development partner Morphosys down 29% Nov 14 (Reuters) – Roche’s (ROG.S) Alzheimer’s drug candidate has not been shown to slow the progression …
Roche’s Alzheimer’s drug fails in long-awaited trial Read More »
As if he hadn’t had enough, Elon Musk will find himself in court later this week to defend his $56 billion salary package against claims by Tesla shareholders that he was rigged with easy performance targets. . And that’s not all ! On Tuesday in Los Angeles, a Tesla Model S owner stands trial for …
WILMINGTON, Del, Nov 14 (Reuters) – A lawsuit opened on Monday over allegations by shareholders that Tesla CEO Elon Musk’s $56 billion pay package was rigged with easy performance targets and that investors were duped into approving it, with Musk expected to take a stand later this week. A Tesla shareholder TSLA.O hopes to prove …
Elon Musk trial opens to decide fate of his $56 billion Tesla salary Read More »
